These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24478054)

  • 1. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.
    Chu GC; Zhau HE; Wang R; Rogatko A; Feng X; Zayzafoon M; Liu Y; Farach-Carson MC; You S; Kim J; Freeman MR; Chung LW
    Endocr Relat Cancer; 2014 Apr; 21(2):311-26. PubMed ID: 24478054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study.
    Hu P; Chung LW; Berel D; Frierson HF; Yang H; Liu C; Wang R; Li Q; Rogatko A; Zhau HE
    PLoS One; 2013; 8(9):e73081. PubMed ID: 24066029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture.
    Ziaee S; Chung LW
    Mol Cancer; 2014 Sep; 13():208. PubMed ID: 25200184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.
    Gupta A; Cao W; Chellaiah MA
    Mol Cancer; 2012 Sep; 11():66. PubMed ID: 22966907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro.
    Casimiro S; Mohammad KS; Pires R; Tato-Costa J; Alho I; Teixeira R; Carvalho A; Ribeiro S; Lipton A; Guise TA; Costa L
    PLoS One; 2013; 8(5):e63153. PubMed ID: 23696795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
    Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
    J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK-mediated signaling network and cancer metastasis.
    Chu GC; Chung LW
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):497-509. PubMed ID: 24398859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
    Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
    World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.
    Uehara H; Takahashi T; Izumi K
    Int J Oncol; 2013 Aug; 43(2):365-74. PubMed ID: 23708710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
    Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
    Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
    Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
    J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
    Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.
    Odero-Marah VA; Wang R; Chu G; Zayzafoon M; Xu J; Shi C; Marshall FF; Zhau HE; Chung LW
    Cell Res; 2008 Aug; 18(8):858-70. PubMed ID: 18645583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
    Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
    PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
    Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.